Particle Physics

J. Ellis, G.L. Fogli, "New bounds on mt and first bounds on MH from precision electroweak data," Physics Letters B, 249:543-50, 1990. John Ellis (CERN, Geneva, Switzerland): "The Standard Model needs two as-yet-undiscovered particles for its completion: the top quark, which is heavier than the other five quarks that make up all known nuclear matter; and the Higgs boson, which would originate the masses of all the elementary particles. These undiscovered particles now constitute the `Holy Grai

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

J. Ellis, G.L. Fogli, "New bounds on mt and first bounds on MH from precision electroweak data," Physics Letters B, 249:543-50, 1990.

John Ellis (CERN, Geneva, Switzerland): "The Standard Model needs two as-yet-undiscovered particles for its completion: the top quark, which is heavier than the other five quarks that make up all known nuclear matter; and the Higgs boson, which would originate the masses of all the elementary particles. These undiscovered particles now constitute the `Holy Grail' of particle physics. "Although no accelerator has yet produced these particles, their masses and, hence, the energies required can be estimated on the basis of their subtle quantum effects in lower- energy experiments. With the precise data made possible by the new LEP accelerator at CERN, we were able to estimate the mass of the top quark with a precision of about 20 percent and give the first indications on the mass of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies